Chemours (CC)
(Delayed Data from NYSE)
$19.44 USD
+0.10 (0.52%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $19.44 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$19.44 USD
+0.10 (0.52%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $19.44 0.00 (0.00%) 7:58 PM ET
5-Strong Sell of 5 5
D Value F Growth D Momentum F VGM
Zacks News
Best Value Stocks to Buy for June 27th
by Zacks Equity Research
CPLP, CC, and DELL made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 27, 2022.
Best Income Stocks to Buy for June 27th
by Zacks Equity Research
BSAC, CPLP, and CC made it to the Zacks Rank #1 (Strong Buy) income stocks list on June 27, 2022.
Chemours (CC) Stock Jumps 7.4%: Will It Continue to Soar?
by Zacks Equity Research
Chemours (CC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
CC vs. FMC: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
CC vs. FMC: Which Stock Is the Better Value Option?
Are Investors Undervaluing Chemours (CC) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Momentum Stocks to Buy for June 22nd
by Zacks Equity Research
CC, KR, and OSBC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 22, 2022.
Chemours (CC) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Chemours (CC) closed the most recent trading day at $31.44, moving -0.47% from the previous trading session.
Nutrien (NTR) to Increase Fertilizer Production & Return Capital
by Zacks Equity Research
Nutrien (NTR) intends to boost annual potash manufacturing capacity to 18 million tons by 2025 due to the supply uncertainty from Eastern Europe.
U.S. Silica (SLCA) Completes Review of ISP Unit Alternatives
by Zacks Equity Research
U.S. Silica's (SLCA) Board determines that retaining ownership of the ISP segment would be the best path forward.
Univar (UNVR) Expands Collaboration With BASF, Boosts Portfolio
by Zacks Equity Research
Univar (UNVR) expands its partnership with BASF to better serve customers through a range of sustainable solutions across various applications.
Is Chemours (CC) Stock Outpacing Its Basic Materials Peers This Year?
by Zacks Equity Research
Here is how Chemours (CC) and Cabot (CBT) have performed compared to their sector so far this year.
Sherwin-Williams (SHW) Inks Deal to Buy Gross & Perthun GmbH
by Zacks Equity Research
Sherwin-Williams' (SHW) deal with Gross & Perthun GmbH provides multiple opportunities to boost profitable growth throughout Europe and beyond.
Air Products (APD) Inks Long-Term Supply Deal With IOCL
by Zacks Equity Research
Air Products (APD) will build, own and operate a new industrial gases complex providing hydrogen, nitrogen and steam to IOCL's Barauni Refinery.
ScottsMiracle-Gro (SMG) Lowers Sales and EPS Outlook for FY22
by Zacks Equity Research
ScottsMiracle-Gro's (SMG) adjusted earnings per share are now projected between $4.50 to $5.
Cabot (CBT) Prices 5% Senior Notes Due 2032 Worth $400 Million
by Zacks Equity Research
Cabot's (CBT) notes are being sold to the public at 99.33% of the face amount.
US Chemicals Set for Solid Growth Despite Supply Chaos: 5 Picks
by Anindya Barman
The U.S. chemical industry is poised for strong upside this year on healthy end-market demand and inventory rebuilding. HUN, ALB, KRO, CC and UNVR are good options for investment right now.
Chemours (CC) Stock Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Chemours (CC) benefits from a rebound in demand from the pandemic-induced downturn, strong execution, cost-reduction and pricing actions.
Chemours (CC) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Chemours (CC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
New Strong Buy Stocks for June 7th
by Zacks Equity Research
SBLK, GOGL, LPX, ASRT, and CC have been added to the Zacks Rank #1 (Strong Buy) List on June 7, 2022.
Best Value Stocks to Buy for June 7th
by Zacks Equity Research
LPX, GOGL, and CC made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 7, 2022.
Is Chemours (CC) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Best Value Stocks to Buy for June 3rd
by Zacks Equity Research
AMR, MBUU, and CC made it to the Zacks Rank #1 (Strong Buy) value stocks list on June 3, 2022.
Cabot (CBT) Shares Hit 52-week High: What's Driving It?
by Zacks Equity Research
Cabot (CBT) is gaining from a recovery in demand and strategic acquisitions.
Why Is Chemours (CC) Up 10.7% Since Last Earnings Report?
by Zacks Equity Research
Chemours (CC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest In Chemours (CC) Stock Now
by Zacks Equity Research
Chemours (CC) is gaining from higher volumes on the back of strong demand, its cost and pricing actions and strong execution.